Technical Analysis for NBY - NovaBay Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade F 1.35 -4.26% -0.06
NBY closed down 4.26 percent on Tuesday, March 19, 2019, on 28 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Earnings due: Mar 28

*** please verify all earnings dates ***

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Down
See historical NBY trend table...

Date Alert Name Type % Chg
Mar 19 20 DMA Resistance Bearish 0.00%
Mar 19 Stochastic Reached Oversold Weakness 0.00%
Mar 19 Outside Day Range Expansion 0.00%
Mar 19 Down 3 Days in a Row Weakness 0.00%
Mar 19 Oversold Stochastic Weakness 0.00%
Mar 18 Narrow Range Bar Range Contraction -4.26%
Mar 18 NR7 Range Contraction -4.26%
Mar 18 NR7-2 Range Contraction -4.26%
Mar 18 Inside Day Range Contraction -4.26%
Mar 15 Calm After Storm Range Contraction -5.06%

Older signals for NBY ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

NovaBay Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the development of various product candidates for the therapeutic needs of the anti-infective market. The company operates in four segments: Dermatology, Ophthalmology, Urology, and Wound Care. It has categories of compounds, Aganocides and NeutroPhase. The company's Aganocide compounds comprise NVC-422 that is in Phase IIb clinical study for the treatment of adenoviral conjunctivitis, a contagious viral eye infection; impetigo, a highly contagious skin infection; and urinary catheter blockage and encrustation, and associated urinary tract infections. Its NeutroPhase product is a hypochlorous acid solution, has approved for the treatment of patients who suffer from chronic non-healing wounds, such as pressure, venous stasis, and diabetic ulcers. The company has collaboration and license agreement with Galderma S.A. to develop and commercialize its Aganocide compounds, which covers acne, impetigo, and other dermatological conditions. It also has strategic marketing agreement with Pioneer Pharma Co., Ltd. to market its pharmaceutical products in China and other Asian markets. The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007. NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is based in Emeryville, California.
Medicine Health Biotechnology California Pharmaceutical Products Catheter Acne Urinary Tract Infections Impetigo
Is NBY a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 3.85
52 Week Low 0.71
Average Volume 25,272
200-Day Moving Average 1.684
50-Day Moving Average 1.4565
20-Day Moving Average 1.4346
10-Day Moving Average 1.4213
Average True Range 0.1421
ADX 19.6
+DI 26.5725
-DI 19.0658
Chandelier Exit (Long, 3 ATRs ) 1.3237
Chandelier Exit (Short, 3 ATRs ) 1.7563
Upper Bollinger Band 1.5856
Lower Bollinger Band 1.2836
Percent B (%b) 0.22
BandWidth 21.051164
MACD Line -0.027
MACD Signal Line -0.0184
MACD Histogram -0.0087
Fundamentals Value
Market Cap 20.67 Million
Num Shares 15.3 Million
EPS -0.79
Price-to-Earnings (P/E) Ratio -1.71
Price-to-Sales 4.39
Price-to-Book 20.95
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.52
Resistance 3 (R3) 1.53 1.49 1.49
Resistance 2 (R2) 1.49 1.45 1.48 1.48
Resistance 1 (R1) 1.42 1.42 1.40 1.41 1.47
Pivot Point 1.38 1.38 1.37 1.37 1.38
Support 1 (S1) 1.31 1.34 1.29 1.30 1.23
Support 2 (S2) 1.27 1.31 1.26 1.22
Support 3 (S3) 1.20 1.27 1.21
Support 4 (S4) 1.19